RRM2 and cancer: Three of those six hub genes were found to be significantly differentiated in various clinical stages, including RRM2, DTL, and KIF15. In addition, to explore relationships between genes and drugs, CBio Cancer Genomics Portal (cBioPortal) was used and showed that TOP2A and RRM2 were the targets of cancer drugs in patients with OC, indicating the other four genes may also be potential drug targets.